



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: GUPADT

DOCTOR'S ORDERS																			
Ht _____ cm Wt _____ kg BSA _____ m ²																			
REMINDER: Please ensure drug allergies and previous bleomycin are documented on the Allergy & Alert Form																			
DATE: _____																			
TREATMENT:																			
<p>Patient will be receiving injections via: (select one option)</p> <p><input type="checkbox"/> Manufacturer home injection program</p> <p><input type="checkbox"/> BC Cancer regional center</p> <p><input type="checkbox"/> Alternate healthcare provider</p> <p><input type="checkbox"/> Community Oncology Network (CON) site</p> <p>Choose one of the injection options below:</p> <table style="width: 100%;"><tr><td style="width: 40%;">goserelin long acting (ZOLADEX)</td><td><input type="checkbox"/> 3.6 mg subcutaneous every month x _____ doses</td></tr><tr><td>goserelin long acting (ZOLADEX LA)</td><td><input type="checkbox"/> 10.8 mg subcutaneous every 3 months x _____ doses</td></tr></table> <p>OR</p> <table style="width: 100%;"><tr><td style="width: 40%;">leuprolide long acting (LUPRON DEPOT)</td><td><input type="checkbox"/> 7.5 mg IM every month x _____ doses</td></tr><tr><td>leuprolide long acting (LUPRON DEPOT)</td><td><input type="checkbox"/> 22.5 mg IM every 3 months x _____ doses</td></tr><tr><td>leuprolide long acting (LUPRON DEPOT)</td><td><input type="checkbox"/> 30 mg IM every 4 months x _____ doses</td></tr></table> <p>OR</p> <table style="width: 100%;"><tr><td style="width: 40%;">leuprolide long acting (ELIGARD)</td><td><input type="checkbox"/> 7.5 mg subcutaneous every month x _____ doses</td></tr><tr><td>leuprolide long acting (ELIGARD)</td><td><input type="checkbox"/> 22.5 mg subcutaneous every 3 months x _____ doses</td></tr><tr><td>leuprolide long acting (ELIGARD)</td><td><input type="checkbox"/> 30 mg subcutaneous every 4 months x _____ doses</td></tr><tr><td>leuprolide long acting (ELIGARD)</td><td><input type="checkbox"/> 45 mg subcutaneous every 6 months x _____ doses</td></tr></table> <p>OR</p> <p>degarelix <input type="checkbox"/> 240 mg subcutaneous (as two injections of 120 mg) loading dose on day 1</p> <p><input type="checkbox"/> 80 mg subcutaneous (single injection) every month x _____ doses</p> <p>Injections to be given in abdominal region. To reduce incidence of injection site reactions, withdraw needle from patient 30 seconds post injection.</p>		goserelin long acting (ZOLADEX)	<input type="checkbox"/> 3.6 mg subcutaneous every month x _____ doses	goserelin long acting (ZOLADEX LA)	<input type="checkbox"/> 10.8 mg subcutaneous every 3 months x _____ doses	leuprolide long acting (LUPRON DEPOT)	<input type="checkbox"/> 7.5 mg IM every month x _____ doses	leuprolide long acting (LUPRON DEPOT)	<input type="checkbox"/> 22.5 mg IM every 3 months x _____ doses	leuprolide long acting (LUPRON DEPOT)	<input type="checkbox"/> 30 mg IM every 4 months x _____ doses	leuprolide long acting (ELIGARD)	<input type="checkbox"/> 7.5 mg subcutaneous every month x _____ doses	leuprolide long acting (ELIGARD)	<input type="checkbox"/> 22.5 mg subcutaneous every 3 months x _____ doses	leuprolide long acting (ELIGARD)	<input type="checkbox"/> 30 mg subcutaneous every 4 months x _____ doses	leuprolide long acting (ELIGARD)	<input type="checkbox"/> 45 mg subcutaneous every 6 months x _____ doses
goserelin long acting (ZOLADEX)	<input type="checkbox"/> 3.6 mg subcutaneous every month x _____ doses																		
goserelin long acting (ZOLADEX LA)	<input type="checkbox"/> 10.8 mg subcutaneous every 3 months x _____ doses																		
leuprolide long acting (LUPRON DEPOT)	<input type="checkbox"/> 7.5 mg IM every month x _____ doses																		
leuprolide long acting (LUPRON DEPOT)	<input type="checkbox"/> 22.5 mg IM every 3 months x _____ doses																		
leuprolide long acting (LUPRON DEPOT)	<input type="checkbox"/> 30 mg IM every 4 months x _____ doses																		
leuprolide long acting (ELIGARD)	<input type="checkbox"/> 7.5 mg subcutaneous every month x _____ doses																		
leuprolide long acting (ELIGARD)	<input type="checkbox"/> 22.5 mg subcutaneous every 3 months x _____ doses																		
leuprolide long acting (ELIGARD)	<input type="checkbox"/> 30 mg subcutaneous every 4 months x _____ doses																		
leuprolide long acting (ELIGARD)	<input type="checkbox"/> 45 mg subcutaneous every 6 months x _____ doses																		
DOCTOR'S SIGNATURE:	SIGNATURE:																		
	UC:																		



Provincial Health Services Authority

Information on this form is a guide only. User will be solely responsible for verifying its currency and accuracy with the corresponding BC Cancer treatment protocols located at www.bccancer.bc.ca/terms-of-use and according to acceptable standards of care.

PROTOCOL CODE: GUPADT

DATE:	
TREATMENT: (continued)	
If required, choose one of the oral options below:	
<input type="checkbox"/> bicalutamide 50 mg PO daily	
<input type="checkbox"/> flutamide 250 mg PO TID	
Supply for: _____ days. Repeat x _____	
RETURN APPOINTMENT ORDERS	
<input type="checkbox"/> Return in _____ months for Doctor.	
If clinically indicated: <input type="checkbox"/> PSA <input type="checkbox"/> testosterone	
For patients taking flutamide, every 3 months: <input type="checkbox"/> total bilirubin <input type="checkbox"/> ALT <input type="checkbox"/> alkaline phosphatase	
<input type="checkbox"/> Other tests:	
<input type="checkbox"/> Consults:	
<input type="checkbox"/> See general orders sheet for additional requests.	
DOCTOR'S SIGNATURE:	SIGNATURE:
	UC: